Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial

Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancer

Hosted by: 

Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA

Featuring: 

Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USA

Ramez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USA


Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Gynecologic Oncology. Innehållet i podden är skapat av Gynecologic Oncology och inte av, eller tillsammans med, Poddtoppen.